This is consistent with findings from the DESTINY-Breast01 clinical trial, where DS8201 exhibited durable anti-tumor activity in patients with HER2-positive metastatic breast cancer who were previously treated with ADCs. The gene discussed is ERBB2; the disease is neoplasm.